Vioxx, a lucrative arthritis drug, faced global withdrawal by Merck due to increased stroke and heart attack risks.
The European Medicines Agency reviewed COX-2 inhibitors, including Vioxx, but initially deemed them safe.
However, subsequent studies revealed alarming cardiovascular dangers, prompting Merck's decision.
Lawsuits against Merck surged, alleging negligence in disclosing risks.
The FDA estimated thousands of heart attacks linked to Vioxx.
Despite ongoing legal battles, questions linger about the drug's safety and the company's accountability.
The Vioxx saga serves as a cautionary tale of pharmaceutical controversies and patient safety concerns.
